title: [The efficacy of Shakuyaku-Kanzo-to for peripheral nerve dysfunction in paclitaxel combination chemotherapy for epithelial ovarian carcinoma].
abstract: Shakuyaku-Kanzo-to was first medicated for muscular pain which was called Komuragaeri, and it has been reported that it is effective for peripheral nerve dysfunction such as arthralgia and numbness. Recently, Paclitaxel (T) and Carboplatin (J) combination chemotherapy (TJ chemotherapy) has been a standard first-line chemotherapy for epithelial ovarian carcinoma. For the arthralgia and muscular pain occurring in TJ chemotherapy, non-steroid-anti-inflammatory drugs (NSAIDs), Vitamin B12 (VB12) and Shakuyaku-Kanzo-to are the major medications. In this study, we examined twenty-one cases in which arthralgia and muscular pain occurred in TJ chemotherapy (including 16 cases as first-line chemotherapy). In all cases, patients took 7.5 g of Shakuyaku-Kanzo-to orally per day for eight days. We investigated the efficacy of Shakuyaku-Kanzo-to retrospectively with the following results. In nine cases (43%), Shakuyaku-Kanzo-to was effective in reducing pain. Especially in TJ chemotherapy as first-line chemotherapy, Shakuyaku-Kanzo-to was even more effective in reducing pain. We suggested that Paclitaxel combination chemotherapy with Shakuyaku-Kanzo-to taken orally is a more safe and tolerable way to reduce pain in epithelial ovarian carcinoma.
authors.affiliation: Dept. of Obstetrics and Gynecology, National Defense Medical College.
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Fujii
authors.forename: Sanshirou
authors.initials: S
authors.lastname: Okamoto
authors.forename: Keiko
authors.initials: K
authors.lastname: Saitoh
authors.forename: Naoki
authors.initials: N
authors.lastname: Sasaki
authors.forename: Masashi
authors.initials: M
authors.lastname: Takano
authors.forename: Souichirou
authors.initials: S
authors.lastname: Tanaka
authors.forename: Kazuya
authors.initials: K
authors.lastname: Kudoh
authors.forename: Tsunekazu
authors.initials: T
authors.lastname: Kita
authors.forename: Takehiko
authors.initials: T
authors.lastname: Tode
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Kikuchi
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018771:Arthralgia / Q000188:drug therapy; D016190:Carboplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006035:Glycyrrhiza; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000150:complications / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage; D029596:Paeonia; D010523:Peripheral Nervous System Diseases / Q000188:drug therapy* / Q000209:etiology
chemical_list: D004338:Drug Combinations; D004365:Drugs, Chinese Herbal; C038462:shakuyaku-kanzoh-toh; D016190:Carboplatin; D017239:Paclitaxel